Antibody pharmacokinetics and pharmacodynamics

ED Lobo, RJ Hansen, JP Balthasar - Journal of pharmaceutical sciences, 2004 - Elsevier
Abstract The US Food and Drug administration (FDA) has approved several polyclonal
antibody preparations and at least 18 monoclonal antibody preparations (antibodies …

Elimination mechanisms of therapeutic monoclonal antibodies

MA Tabrizi, CML Tseng, LK Roskos - Drug discovery today, 2006 - Elsevier
Targeted therapies using monoclonal antibodies have achieved important therapeutic
applications in the treatment of various human diseases. Understanding the factors that …

Resistance to trastuzumab in breast cancer

PR Pohlmann, IA Mayer, R Mernaugh - Clinical cancer research, 2009 - AACR
HER2 is a transmembrane oncoprotein encoded by the HER2/neu gene and is
overexpressed in approximately 20 to 25% of invasive breast cancers. It can be …

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune …

SB Petkova, S Akilesh, TJ Sproule… - International …, 2006 - academic.oup.com
The MHC class I-like Fc receptor FcRn plays an essential role in extending the half-life (t 1/2)
of IgG antibodies and IgG-Fc-based therapeutics in the circulation. The goal of this study …

Optimized Fc variants

GA Lazar, AJ Chirino, W Dang, JR Desjarlais… - US Patent …, 2008 - Google Patents
2004-11-10 Assigned to XENCOR, INC. reassignment XENCOR, INC. ASSIGNMENT OF
ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DANG, WEI …

Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro

J Hodoniczky, YZ Zheng, DC James - Biotechnology progress, 2005 - Wiley Online Library
N‐Glycans at Asn297 in the Fc domain of IgG molecules are required for Fc receptor‐
mediated effector functions such as antibody‐dependent cell‐mediated cytotoxicity (ADCC) …

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

NS Wilson, B Yang, A Yang, S Loeser, S Marsters… - Cancer cell, 2011 - cell.com
Antibodies to cell-surface antigens trigger activatory Fcγ receptor (FcγR)-mediated
retrograde signals in leukocytes to control immune effector functions. Here, we uncover an …

Optimized FC variants

GA Lazar, W Dang, JR Desjarlais, SB Karki… - US Patent …, 2012 - Google Patents
2005-09-29 Assigned to XENCOR, INC. reassignment XENCOR, INC. ASSIGNMENT OF
ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAYES, ROBERT …

Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies

M Dostalek, I Gardner, BM Gurbaxani, RH Rose… - Clinical …, 2013 - Springer
Abstract Development of monoclonal antibodies (mAbs) and their functional derivatives
represents a growing segment of the development pipeline in the pharmaceutical industry …

Targeted therapy of cancer: new prospects for antibodies and immunoconjugates

RM Sharkey, DM Goldenberg - CA: a cancer journal for …, 2006 - Wiley Online Library
ABSTRACT Immunotherapy of cancer has been explored for over a century, but it is only in
the last decade that various antibody‐based products have been introduced into the …